Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02909972 · ClinicalTrials.gov registry record · Phase 1

Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Aileron Therapeutics.

Completed
Registry status
Phase 1
Development phase
55
Enrollment target
6
Study locations

NCT02909972 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that has completed, run by Aileron Therapeutics. The registered enrollment target is 55 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (53% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02909972, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Aileron Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
55 participants
Enrollment target
6
Study locations

Study Summary

Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 alone or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia or advanced myelodysplastic syndrome with wild-type (WT) TP53

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndromes

Interventions

  • DRUG ALRN-6924
  • DRUG ALRN-6924 in combination with cytarabine

Study Locations (6)

Colorado

  • - Denver

Florida

  • - Tampa

New York

  • - The Bronx

Oregon

  • - Portland

South Carolina

  • - Greenville

Tennessee

  • - Nashville

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2016-09
Est. Completion 2019-08
Phase Phase 1

Sponsor

Aileron Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02909972

The ClinicalTrials.gov registry entry for NCT02909972 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (53% lower). The listed sponsor is Aileron Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which ALRN-6924 is the first listed.

NCT02909972 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Colorado, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT02909972 about?

NCT02909972 is a clinical study titled "Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome". Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 alone or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemi...

What is the current status of trial NCT02909972?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2016-09. Estimated completion is 2019-08.

What conditions does trial NCT02909972 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes.

What interventions are being tested in trial NCT02909972?

The interventions under investigation include: ALRN-6924 (DRUG), ALRN-6924 in combination with cytarabine (DRUG).

Who is sponsoring clinical trial NCT02909972?

This trial is sponsored by Aileron Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02909972 being conducted?

This trial has 6 study locations across Colorado, Florida, New York, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndromes

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.